Lilly's obesity pill helps reduce cardiovascular risks in late-stage trial
In the phase 3 ACHIEVE‑4 trial, Eli Lilly’s oral obesity pill Foundayo demonstrated cardiovascular benefit in patients with type 2 diabetes who are overweight or obese and at elevated cardiovascular risk. The study met its primary objective of non‑inferiority to insulin glargine and showed a 16 % lower risk of major adverse cardiovascular events (MACE‑4) and a 23 % lower risk of MACE‑3 (cardiovascular death, non‑fatal myocardial infarction and stroke). Additionally, the trial observed a reduced
Key Points
- In the phase 3 ACHIEVE‑4 trial, Eli Lilly’s oral obesity pill Foundayo demonstrated cardiovascular benefit in patients with type 2 diabetes who are overweight or obese and at elevated cardiovascular risk.
- The study met its primary objective of non‑inferiority to insulin glargine and showed a 16 % lower risk of major adverse cardiovascular events (MACE‑4) and a 23 % lower risk of MACE‑3 (cardiovascular death, non‑fatal myocardial infarction and stroke).
- Additionally, the trial observed a reduced risk of all‑cause death, reinforcing the drug’s cardiovascular safety profile..
Full Details
In the phase 3 ACHIEVE‑4 trial, Eli Lilly’s oral obesity pill Foundayo demonstrated cardiovascular benefit in patients with type 2 diabetes who are overweight or obese and at elevated cardiovascular risk. The study met its primary objective of non‑inferiority to insulin glargine and showed a 16 % lower risk of major adverse cardiovascular events (MACE‑4) and a 23 % lower risk of MACE‑3 (cardiovascular death, non‑fatal myocardial infarction and stroke). Additionally, the trial observed a reduced risk of all‑cause death, reinforcing the drug’s cardiovascular safety profile.
Why It Matters
In the phase 3 ACHIEVE‑4 trial, Eli Lilly’s oral obesity pill Foundayo demonstrated cardiovascular benefit in patients with type 2 diabetes who are overweight or obese and at elevated cardiovascular risk. The study met its primary objective of non‑inferiority to insulin glargine and showed a 16 % lo
Get stories like this delivered daily
AI-curated news, personalized to your interests. Zero noise.
Start 7-Day Free Trial →More in Finance & Markets
Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Hormuz disruptions hit China’s Christmas capital — and holiday spending
Manufacturers told CNBC that shoppers will likely have to pay higher prices to match rising costs of plastic and other materials.
Trump threatens Iran again as ceasefire deadline looms, U.S. gears up for peace talks
Trump reportedly said Sunday that if Iran doesn't sign a deal, "the whole country is going to get blown up," with its bridges and power plants being targeted.
Strait of Hormuz ship traffic briefly rose and then slowed after weekend attacks
Commercial ships remain cautious about transiting the strait as tensions escalate between the U.S. and Iran again.